Trump Pharma Tariffs

Indian drugmakers in no rush to shift to US despite tariff threat

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

US proposal to impose tariffs on generic medicines could impact India: GTRI

The proposed steep tariffs announced by the US on generic medicines could significantly affect India's largest pharmaceutical export market, economic think tank GTRI said on Wednesday. However, it said that the impact is unlikely to be uniform. "Many Indian generic medicines sell for seven to ten times less than branded alternatives. Even after a 100 per cent tariff, many products could remain cheaper than branded medicines, meaning much of the additional cost would likely be passed on to US healthcare providers, insurers and patients rather than immediately eliminating Indian exports," it said. It added that the greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable. "The proposed tariffs could significantly affect India's largest pharmaceutical export market," Global Trade Research Initiative (GTRI) founder Ajay Srivastava said, adding that India should also reduce

Trump's 200% tariff plan on generic drugs: What it means for India

Donald Trump has proposed phased tariffs of up to 200% on imported generic drugs by 2028 to boost US manufacturing. Here's why the move matters for India's pharma sector and bilateral trade

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Trump set to impose fresh tariffs by July 24 with stopgap to expire

The Trump administration last month proposed new tariffs of at least 10 per cent on 60 trading partners, citing what it said were lax forced-labor standards

Trump announces 100% tariff on imported generic drugs from August 2028

Trump has seized on the cost of drugs as a key driver of affordability concerns ahead of the 2026 midterm elections